yttrium radioisotopes has been researched along with Cell Transformation, Neoplastic in 6 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (16.67) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 1 (16.67) | 2.80 |
| Authors | Studies |
|---|---|
| Bui, VC; Dang, HH; Ho, AS; Nguyen, DK; Nguyen, LT; Nguyen, TB; Nguyen, TK; Nguyen, TN; Nguyen, TT | 1 |
| Bäck, TA; Booth, GC; Fisher, DR; Frayo, SL; Frost, SH; Gopal, AK; Green, DJ; Hylarides, MD; Lin, Y; Miller, BW; Orozco, JJ; Pagel, JM; Press, OW | 1 |
| Adam, MJ; Carlin, SD; Carnazza, KE; Edwards, KJ; Lewis, JS; Orvig, C; Price, EW; Zeglis, BM | 1 |
| Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK; Regino, CA; Szajek, LP; Wong, KJ | 1 |
| Baidoo, KE; Brechbiel, MW; Garmestani, K; Milenic, DE; Nayak, TK | 1 |
| Bartlett, NL; Cabanillas, F; Czuczman, MS; Emmanouilides, C; Gordon, LI; Grillo-López, AJ; Joyce, R; Multani, P; Padre, N; Pohlman, BL; White, CA; Wiseman, GA; Witzig, TE | 1 |
1 trial(s) available for yttrium radioisotopes and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Randomized controlled trial of yttrium-90-labeled ibritumomab tiuxetan radioimmunotherapy versus rituximab immunotherapy for patients with relapsed or refractory low-grade, follicular, or transformed B-cell non-Hodgkin's lymphoma.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD19; Antineoplastic Agents; Cell Transformation, Neoplastic; Disease Progression; Disease-Free Survival; Female; Humans; Liver; Lymphoma, B-Cell; Lymphoma, Follicular; Lymphoma, Non-Hodgkin; Male; Middle Aged; Radioimmunotherapy; Radionuclide Imaging; Rituximab; Survival Rate; Treatment Outcome; Yttrium Radioisotopes | 2002 |
5 other study(ies) available for yttrium radioisotopes and Cell Transformation, Neoplastic
| Article | Year |
|---|---|
Efficacy of nimotuzumab (hR3) conjugated with
Topics: Animals; Antibodies, Monoclonal, Humanized; Cell Transformation, Neoplastic; Humans; Iodine Radioisotopes; Laryngeal Neoplasms; Mice; Mice, Nude; Radioimmunotherapy; Yttrium Radioisotopes | 2021 |
Comparative efficacy of 177Lu and 90Y for anti-CD20 pretargeted radioimmunotherapy in murine lymphoma xenograft models.
Topics: Animals; Antigens, CD20; Beta Particles; Cell Line, Tumor; Cell Transformation, Neoplastic; Female; Humans; Immunoconjugates; Lutetium; Lymphoma; Mice; Mice, Nude; Radioimmunotherapy; Tissue Distribution; Xenograft Model Antitumor Assays; Yttrium Radioisotopes | 2015 |
A comparative evaluation of the chelators H4octapa and CHX-A″-DTPA with the therapeutic radiometal (90)Y.
Topics: Animals; Cell Line, Tumor; Cell Transformation, Neoplastic; Chelating Agents; Ethylamines; Female; Isothiocyanates; Isotope Labeling; Mice; Pentetic Acid; Positron-Emission Tomography; Pyridines; Radioimmunotherapy; Tissue Distribution; Trastuzumab; Yttrium Radioisotopes | 2016 |
PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.
Topics: Animals; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Cell Line, Tumor; Cell Transformation, Neoplastic; Cetuximab; ErbB Receptors; Female; Gene Expression Regulation, Neoplastic; Humans; Isothiocyanates; Mice; Neoplasms; Pentetic Acid; Positron-Emission Tomography; Radiochemistry; Yttrium Radioisotopes | 2010 |
Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinoma.
Topics: Animals; Antibodies, Monoclonal; Area Under Curve; Biological Transport; Cell Line, Tumor; Cell Transformation, Neoplastic; ErbB Receptors; Female; Humans; Mice; Neoplasms; Panitumumab; Pentetic Acid; Positron-Emission Tomography; Radiochemistry; Risk Assessment; Yttrium Radioisotopes | 2010 |